Emergent Biosolutions
EBS
209 hedge funds and large institutions have $1.17B invested in Emergent Biosolutions in 2016 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 76 increasing their positions, 67 reducing their positions, and 28 closing their positions.
64% more call options, than puts
Call options by funds: $1.32M | Put options by funds: $804K
32% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 28
13% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 67
2% more funds holding
Funds holding: 204 → 209 (+5)
2.25% less ownership
Funds ownership: 90.5% → 88.25% (-2.2%)
10% less capital inflows, than outflows
Capital inflows: $131M | Capital outflows: $146M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$12M |
| 2 |
BlackRock Fund Advisors
San Francisco,
California
|
+$11.2M |
| 3 |
Peregrine Capital Management
Minneapolis,
Minnesota
|
+$9.05M |
| 4 |
Aberdeen Asset Management
Aberdeen,
United Kingdom
|
+$7.57M |
| 5 |
Snyder Capital Management
San Francisco,
California
|
+$5.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$23.3M |
| 2 |
State Street
Boston,
Massachusetts
|
-$9.3M |
| 3 |
Renaissance Technologies
New York
|
-$8.83M |
| 4 |
Goldman Sachs
New York
|
-$8.42M |
| 5 |
Cormorant Asset Management
Boston,
Massachusetts
|
-$7.88M |
EBS Hedge Fund Activity: Q4 2016 in Review
209 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q4 2016, worth a combined $1.17B — up 1.7% from $1.15B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new EBS positions and 28 closed out — a net gain of 9 holders — while 76 added to existing stakes and 67 trimmed.
The largest buyer was Royal Bank of Canada, adding an estimated $12M. The largest seller was Arrowstreet Capital, exiting entirely with an estimated $23.3M sold.
- 209 institutional investors held Emergent Biosolutions (EBS) as of Q4 2016, up from 204 in Q3 2016.
- Funds reported $1.17B of Emergent Biosolutions stock for Q4 2016, up 1.7% quarter-over-quarter.
- 37 funds opened new Emergent Biosolutions positions in Q4 2016 and 28 closed out, a net change of +9 holders.
- The largest Emergent Biosolutions buyer in Q4 2016 was Royal Bank of Canada, an estimated $12M added.
- The largest Emergent Biosolutions seller in Q4 2016 was Arrowstreet Capital, an estimated $23.3M sold.
Based on aggregated 13F filings for Q4 2016.